Natera Inc
Closed
SectorHealthcare
392.13 -3.02
Overview
Share price change
24h
Min
387.12
Max
409.67
Income | 18M -67M |
|---|---|
Sales | 56M 753M |
EPS | -0.47 |
Profit margin | -8.897 |
Employees | 6,135 |
EBITDA | 20M -45M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | -1.16% downside |
Next Earnings | 5 Nov 2026 |
|---|
Market Cap | 18B 57B |
|---|---|
Previous open | 395.15 |
Previous close | 392.13 |
Natera Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Natera Inc Forecast
Price Target
By TipRanks
-1.16% downside
12 Months Forecast
Average 400.079 USD -1.16%
High 480 USD
Low 320 USD
Based on 20 Wall Street analysts offering 12 month price targets forNatera Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Natera Inc
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
